Sign in
4

Changes in Ownership

Alkermes plc. Filed Acc 0001127602-25-004948

EVP R&D, Chief Medical Officer sold 349,340 shares at an average $33.92 ($11,848,975)

  • EVP R&D, Chief Medical Officer acquired 343,615 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hopkinson Craig C. · EVP R&D, Chief Medical Officer

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2025-02-12 Exercise or conversion : show line 1 in the form 10b5-1 +87,566 $20.03 $1,753,947 151,166 D
2025-02-12 Exercise or conversion : show line 2 in the form 10b5-1 +111,630 $19.34 $2,158,924 262,796 D
2025-02-12 Sale : show line 3 in the form 10b5-1 −171,813 $32.69 $5,616,808 90,983 D
2025-02-12 Sale : show line 4 in the form 10b5-1 −33,108 $33.27 $1,101,470 57,875 D
2025-02-13 Exercise or conversion : show line 5 in the form 10b5-1 +108,833 $31.93 $3,475,038 166,708 D
2025-02-13 Exercise or conversion : show line 6 in the form 10b5-1 +35,586 $24.59 $875,060 202,294 D
2025-02-13 Sale : show line 7 in the form 10b5-1 −35,586 $34.02 $1,210,696 166,708 D
2025-02-13 Sale : show line 8 in the form 10b5-1 −108,833 $36.02 $3,920,001 57,875 D
Open-market sales · 349,340 sh · avg $33.92 · $11,848,975

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2025-02-12 Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (Right to Buy) −87,566 0 D
2025-02-12 Exercise or conversion : show line 10 in the form 10b5-1 Employee Stock Option (Right to Buy) −111,630 50,104 D
2025-02-13 Exercise or conversion : show line 11 in the form 10b5-1 Employee Stock Option (Right to Buy) −108,833 0 D
2025-02-13 Exercise or conversion : show line 12 in the form 10b5-1 Employee Stock Option (Right to Buy) −35,586 71,172 D
Loading xslF345X05/form4.xml…